Gyros AB and Affibody AB announce strategic alliance to develop the world’s first microfluidics based protein microarray platform

31-May-2001

Gyros AB and Affibody AB today announced a strategic alliance in which both companies will allocate major resources to develop and commercialize the world’s first integrated and automated microfluidics based protein microarray platform.

The new platform will combine the unique, proprietary technologies of the two companies. CD-based microlaboratories from Gyros together with the extensive libraries of capturing proteins from Affibody will create a wide range of high throughput, high sensitivity protein microarrays.

In the microlaboratory designed for protein microarray applications, a single sample could be evaluated against an array of capturing proteins or many different samples could be evaluated against one or more selected capturing proteins.

Dr. Eugen Steiner, President of Affibody AB commented “Protein microarrays will enable researchers to study cell profiling and protein expression in a rapid and innovative way. The combination of Gyros’ flexible technology platform, together with the versatility of our Affibodies”, underlines our commitment to enable large scale proteomic research in drug discovery.”

“Combining these complementary technologies will give pharmaceutical and diagnostic companies access to exciting, leading edge research tools to enhance the drug discovery process and support the development of new diagnostic, prognostic and therapeutic products for human disease management,” says Dr. Maris Hartmanis, President and CEO of Gyros AB in Uppsala, Sweden.

“In proteomic research, the demand for increased throughput, sensitivity and flexibility continues to grow” says Per Sjöberg, Executive Vice President Commercial Operations at Gyros AB. “By miniaturizing and integrating protein arrays onto our microlaboratories, investigators can perform high throughput protein profiling with minimal consumption of valuable samples. This unique approach will offer a major increase in speed and cost efficiency.”

For reliable data the quality and functionality of the capturing protein is crucial. Affibody has a strong intellectual property position around the patented technique for development of Affibodies™. These capturing proteins can be designed to bind to any desired target protein. Using combinatorial protein engineering technology applied on a proprietary scaffold with excellent features, Affibodies™ can be engineered to have the desired properties, while also being highly robust to withstand a broad range of analytical conditions used in protein microarrays and clinical diagnostics.

Based on more than 10 years of research within microfabrication and microfluidic technology, Gyros has a leading position in the fields of microfabrication and microfluidic technology. This lead is supported by a strong proprietary technology platform with more than 30 patents and patent applications. The company has extensive knowledge concerning the physical and chemical conditions required to provide optimal environments for studying biomolecules in a microscale.


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.